The Company believes INO – 8875, a highly selective adenosine-1 receptor agonist, has considerable potential, either as a monotherapy or in combination with other glaucoma products, because it again clearly, the outflow of aqueous humor through the trabecular meshwork which lower IOP. INO – 8875 has also shown significant additive IOP-lowering effect, when combined with the leading glaucoma product in a preclinical model, suggesting that the mechanism may add to the mechanism of the other glaucoma products.
Current products for glaucoma, such as beta-blockers and prostaglandins, lower IOP by reducing inflow of fluid in the eye or increasing its drainage through a secondary pathway in the eye – the uveoscleral pathway. As glaucoma advances with age increases the natural drainage way through the eye trabecular meshwork trabecular meshwork and increasingly, not surprisingly, a significant %age of patients. Inadequate on the currently approved products elsewhere elsewhere In fact, up to 40 percent of patients have a combination of products in the hope of target IOP and stemming vision loss are discussed. As a result, there remains a unmet need for innovative glaucoma products, when combinedcy.Brachytherapy is a proven1 treatment for early localized prostate cancer. It is implanting tiny radioactive seeds directly into the prostate to kill cancer cells. The seeds are implanted, but naturally deteriorate over time. 2004, common surgery or brachytherapy pinhole surgery be minimally invasive and usually work than a day in proceedings with male and normal daily activities more quickly performed. Side effects side effect profile lower less risks of incontinence and impotence than other treatment options.3.
Credentials1 Radical prostatectomies, external beam radiotherapy or= 72 Gy , permanent seed implantation and combined seeds / external beam radiation therapy in stage T1-T2 prostate cancer. Kupelian PA, Potters L, Khuntia GB et al. Internationally Journal of Radiation Oncology Microbiology Astronomy 2004, 58 :25-33. By the American Brachytherapy Society.